Anastrozole vs Proviron
FDA Approved vs Well Studied
compatible Researched · 90% Proviron's mild anti-estrogenic effect through aromatase competition can reduce the required dose of anastrozole or other aromatase inhibitors. In many men on standard TRT doses, adding Proviron at 50 mg/day eliminates the need for an AI entirely. When both are used, monitor estradiol to avoid over-suppression, which impairs lipids, joint health, bone density, and libido.
Molecular Data
Anastrozole Proviron
Weight 293.37 Da 304.47 Da
Half-life ~40-50 hours ~12 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) DHT derivative (C20H32O2)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Proviron
01 Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
02 Improved mood, motivation, confidence, and overall sense of well-being
03 Significant enhancement of libido and sexual function
04 Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
05 Harder, drier, more defined physical appearance without water retention
06 Minimal hepatotoxicity due to absence of 17-alpha alkylation
07 May improve sperm quality at low doses in subfertile men
08 Rapid onset of subjective well-being effects (often within days)
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Proviron
Accelerated hair thinning or loss in those predisposed to male pattern baldness (DHT-mediated)
Mild suppression of endogenous testosterone at higher doses (though less suppressive than most AAS)
Oily skin and increased sebum production
Mild HDL cholesterol suppression with extended use
Increased body hair growth
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Prostate cancer (active or history of androgen-sensitive prostate cancer)
Severe liver impairment (though hepatotoxicity risk is minimal)
Breast cancer in males
Hypersensitivity to mesterolone or any excipients
Women who are pregnant or may become pregnant (androgenic effects on fetus)
Research Evidence
Anastrozole Proviron
Status FDA Approved Well Studied
References 5 studies 5 studies
FDA Approved Yes No
More comparisons: Testosterone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.